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The landscape of cancer imaging is being shaped by
advances in oncological treatment. As the genetic and
molecular aberration of cancers and cancer subtypes are
being elucidated, specific cellular pathways and asso-
ciated molecular receptors are recognized as potential
pharmacological targets to modify or arrest cancer
growth. In the past two decades, such targeted therapies
are being developed and are progressively being intro-
duced into the clinics. Broadly, they include monoclonal
antibodies (-abs) targeted against circulating molecules
or membrane receptors; and small molecules (-ibs)
which act intracellularly on biochemical pathways.
A number of molecular targets have been identified in
the past decade in a range of tumours (including prostate,
gastrointestinal stromal, colorectal, melanoma, chronic
myeloid leukaemia, renal, lymphoma and myeloma) for
which there are now approved and effective drugs directed
at specific molecular receptors or cellular pathways. Many
of these act by inhibiting signal transduction, blocking the
signal between receptor activation and cellular prolifera-
tion; while others modify signalling proteins that regulate
cellular functions. Another common mode of action is
inhibiting neovascularization (antiangiogenic or antivascu-
lar), which in turn arrests tumour growth. There are also
tumour vaccines and immunotherapies which stimulate
cytotoxic response to cancer cells.
Although target therapies have been employed with
varying success in cancers, the complexity of tumour
escape pathways and the recognition that monotherapy
alone may not be effective, means that it has not been
possible to fully individualise treatment for patients.
This remains the ultimate goal of cancer management.
However, accurate genetic and molecular tumour profil-
ing is already helping to identify tumour subgroups
enabling more precise treatment to be prescribed.
Precision treatment aims to give the right drug (or com-
bination of drugs) to the right patient at the right time to
optimise tumour cell kill and minimise drug toxicity. In a
wider context, precision treatment is also evolving in sur-
gery and radiotherapy. The advent of robotic surgery
allows more precise control of surgical dissection in some
anatomical areas. In radiotherapy, the evolution from sim-
ple external beam treatment to state-of-the-art stereotactic
body radiotherapy and cyberknife treatment means that
high-dose or hypo-fractionated radiation can be delivered
precisely to small target volumes thereby maximizing cell
kill and reducing peri-tumoural complications.
Cancer imaging remains at the heart of this approach, as
precision treatment mandates precision imaging. In the
era of targeted therapy and precision treatment, cancer
imaging aims to accurately depict disease burden, provide
the roadmap for treatment planning, enable novel assess-
ment of treatment response and yield prognostic informa-
tion. Although conventional imaging remains important;
molecular, functional and hybrid/multiplex imaging are
being developed and utilised.
The depiction of disease sites and metastatic burden
has implications for disease staging and prognostication.
Body diffusion-weighted MRI (DWI) is now widely used
as a contrast mechanism to improve disease detection at
initial diagnosis and at disease relapse; especially for
liver, peritoneal and bone metastases. State-of-the-art
high spatial resolution CT and MRI provide detailed ana-
tomical roadmaps for surgical and radiotherapy planning.
The deployment of functional and molecular imaging
yield additional biological information that can be used to
define biological target volumes for precise radiotherapy
planning. The portfolio of current imaging techniques also
enables us to observe treatment induced changes or
complications; and advance our knowledge in the effects
of radiation, cytotoxic and targeted therapies on normal
tissues.
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As many targeted treatments may be effective without
significant tumour shrinkage, conventional size-based
measurement critieria are often inadequate for determin-
ing treatment effectiveness. Not surprisingly, quantitative
CT, MRI and radiotracer techniques are being used to
provide objective measurements of tumour properties
such as tumour perfusion, water diffusion, metabolism,
hypoxia, cellular proliferation and cell death. As these
techniques become standardised and more widely adopted,
they can provide both unique and corroborative informa-
tion about tumour behaviour.
Nonetheless, there are significant challenges and
opportunities ahead. First, better understanding of
heterogeneity within and between tumours remains an
unmet need. Repeated lines of treatment result in differ-
ential tumour clonal evolution, leading to sub-fractions
of tumour cells which become refractory to treatment.
A better understand of the onset and nature of resistant
phenotypes is likely to contribute to the design of more
effective future treatment regimes. Second, there is a
huge opportunity to develop multiplex imaging on
hybrid imaging systems (e.g. PET-MRI) to improve our
understanding of intra- and inter-tumour variations, and
the identification of imaging phenotypes associated with
treatment resistance and poor prognosis. Such informa-
tion can be combined with genomics and other molecu-
lar profiles on a common informatics platform to
provide a rich matrix for data mining and hypothesis
testing. Third, more translational research using human
analogous animal models, where available, would make
a significant contribution to the understanding of the
disease and treatment by providing histological and
molecular validation for both mechanistic and therapeu-
tic drug studies. Fourth, it is necessary to align future
workforce and imaging practices between the historical
domains of radiology and nuclear medicine. The devel-
opment of an integrated research and service strategy
between these disciplines would be critical for the future
success of multimodal multiplex imaging. Last but not
least, in an age where imaging sciences are being
increasingly commoditized, it is important for imaging
specialists to add value by active engagement in clinical
decision-making and management discussions, so that
our practice remains current and relevant to the rapidly
changing oncological practice.
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